Editorial review
Educational content is reviewed for source quality, clinical boundaries, and readability. It is not medical advice; confirm care decisions with a licensed clinician.
The Drug Supply Chain Security Act (DSCSA) generally does not reach compounded ketamine the way it reaches branded pharmaceutical products. How DSCSA affects telehealth ketamine supply comes down to one key fact: compounded preparations, including the sublingual ketamine troches many telehealth platforms dispense, are exempt from the DSCSA's serialization and electronic track-and-trace requirements. Passed in 2013 as Title II of the Drug Quality and Security Act (DQSA), the DSCSA built a national system to identify and trace certain prescription drugs as they move through manufacturers, distributors, and pharmacies. Compounded medications sit outside that system, which changes how these products are quality-checked and what patients should ask their provider before starting treatment.
Quick Answer
DSCSA track-and-trace requirements generally do not apply to compounded ketamine dispensed through telehealth programs, because compounded preparations are exempt from the law's serialization rules. Compounding pharmacies still answer to state boards of pharmacy, USP Chapter 795 standards, FDA oversight under the DQSA, and DEA controlled substance rules, so quality assurance rests on the pharmacy's own practices rather than a federal electronic tracking system. Patients should ask their telehealth provider which pharmacy compounds their medication and what testing that pharmacy performs.
The Drug Supply Chain Security Act (DSCSA) is a federal law that requires manufacturers, distributors, pharmacies, and other supply chain participants to build an electronic, interoperable system for tracing certain prescription drugs. According to the U.S. Food and Drug Administration, the law outlines steps to build a system that identifies and traces prescription drugs as they move through the U.S. supply chain, with full interoperable tracing requirements phased in through November 2023 after several enforcement delays. Under the law, supply chain participants must:
- Maintain product identifiers, including standardized serialization and barcoding
- Maintain transaction information and documentation for each sale
- Participate in electronic data exchange for product tracing
- Respond to reports of suspect or illegitimate product
Compounded preparations are generally exempt from the DSCSA's serialization and track-and-trace requirements. The law applies to prescription drugs as defined under Section 503 of the Federal Food, Drug, and Cosmetic Act. Compounded medications, which are not FDA-approved products and are prepared for individual patients under a prescription, fall outside the manufacturing and distribution rules built for branded pharmaceutical products. In practice, this means the compounded sublingual ketamine troches many telehealth ketamine programs dispense do not carry the serialized product identifiers or move through the electronic tracing systems that apply to manufacturer-distributed drugs.
The Upside of the Exemption
- Compounding pharmacies avoid the cost of building DSCSA serialization and electronic data interchange systems, which helps keep compounded ketamine accessible and reasonably priced.
- Lower infrastructure requirements let smaller, specialized compounding pharmacies keep serving telehealth ketamine programs without the overhead large manufacturers carry.
The Tradeoff
- There is no federal electronic track-and-trace system for compounded ketamine, so tracing a quality issue, contamination event, or diversion problem back through the supply chain depends more on paper records and each pharmacy's internal documentation.
- Patients and providers cannot verify a compounded product's chain of custody the way they could with a DSCSA-serialized branded drug.
DSCSA track-and-trace does not apply, but compounded ketamine dispensed through telehealth programs is not unregulated. Four other layers of oversight apply.
State Board of Pharmacy Oversight. State pharmacy boards license and inspect compounding pharmacies and set quality requirements. A compounding pharmacy serving telehealth ketamine patients must hold a license, often a nonresident pharmacy license, in every state where it dispenses. Our state pharmacy rules guide explains how these requirements vary by state.
USP Standards. Compounding pharmacies are expected to follow USP Chapter 795, the United States Pharmacopeia's standard for non-sterile compounded preparations, which sets requirements for facility conditions, equipment, materials, and quality control relevant to sublingual troche compounding.
FDA Oversight of 503A Pharmacies. The FDA retains oversight authority over compounding pharmacies under the DQSA even though DSCSA track-and-trace does not apply. The agency can inspect 503A pharmacies, issue warning letters, and pursue enforcement action against facilities that fall short of applicable standards.
DEA Controlled Substance Requirements. Because ketamine is a Schedule III controlled substance, the pharmacy must also meet DEA requirements for records maintenance, security, and reporting to state prescription drug monitoring programs.
This layered oversight is separate from federal enforcement actions targeting unlicensed online ketamine sellers, which involve different legal issues than DSCSA compliance. See our coverage of the federal investigation into online ketamine sellers for that distinction.
Some telehealth ketamine platforms source preparations from 503B outsourcing facilities instead of, or in addition to, traditional 503A compounding pharmacies. 503B facilities are FDA-registered and follow current good manufacturing practice standards that are closer to those used in traditional pharmaceutical manufacturing, though they are still not subject to the full DSCSA serialization requirements that apply to manufacturer-distributed finished drugs. If a telehealth ketamine platform uses a 503B facility for some of its preparations, that generally signals a higher level of quality assurance than sourcing exclusively from a 503A compounding pharmacy.
What Patients Should Do
- Understand that your medication has not been serialized the way a pharmacy-dispensed branded drug would be. This is normal for compounded products, not a red flag on its own.
- Ask your telehealth provider which compounding pharmacy they use and what quality checks, such as potency testing or certificates of analysis, that pharmacy performs.
- Follow storage instructions closely, since compounded troches typically require refrigeration and have not undergone the same stability testing as FDA-approved drugs.
- Contact your pharmacy and provider before using a dose that looks, smells, or feels different from previous shipments.
The Bigger Picture
DSCSA's compounding exemption is not a reason to avoid telehealth ketamine, but it does shift more of the quality-assurance burden onto the pharmacy itself. Because there is no mandatory electronic traceability system for compounded ketamine, the pharmacy's internal testing and documentation practices matter more, not less. Choosing a telehealth platform that partners with a licensed, well-documented compounding pharmacy is the most direct way to manage this gap. Our provider verification guide has more on evaluating the pharmacies a telehealth platform partners with.
Learn More
Have questions about how a telehealth ketamine provider sources and verifies its medication?
Frequently Asked Questions
Indirectly, yes. Because the exemption spares compounding pharmacies the cost of building DSCSA serialization and electronic tracing systems, compounded ketamine can generally stay more affordable than it would if those infrastructure requirements applied.
Safety depends on the individual pharmacy's practices rather than a federal tracking system. State board of pharmacy licensing, USP Chapter 795 compliance, and FDA oversight under the DQSA all still apply, so ask your provider which pharmacy they use and what quality testing that pharmacy performs.
A 503A pharmacy compounds medications for individual patients under a specific prescription, while a 503B outsourcing facility is FDA-registered and follows current good manufacturing practice standards closer to traditional drug manufacturing. Neither is subject to full DSCSA serialization, but 503B facilities generally face more FDA oversight.
- StatPearls: Ketamine, comprehensive clinical reference on ketamine pharmacology and therapeutic use
- PubChem: Ketamine Compound Summary, NCBI chemical database entry with molecular data and pharmacokinetics
- MedlinePlus: Ketamine, National Library of Medicine consumer drug information
- HHS: Telehealth, U.S. Department of Health and Human Services guide to telehealth regulations and resources
- SAMHSA National Helpline, free, confidential treatment referral and information service
Share
Related Reading
Have a question about this topic?
Use the contact page when you need to send feedback, request a correction, or ask about the resource.